Literature DB >> 17143155

Propofol for the management of emergence agitation after electroconvulsive therapy: review of a case series.

John P O'Reardon1, Nadia Takieddine, Catherine J Datto, John G Augoustides.   

Abstract

We report the successful use of propofol in the management of a case series (n = 10) of patients with severe, treatment-resistant, postictal agitation (PIA) in the setting of electroconvulsive therapy (ECT). Despite prior inadequate response to intravenous midazolam and other agents, propofol therapy was highly effective with good control of PIA achieved in all cases. Propofol was well tolerated with occasional, transient, and reversible drops in blood the pressure being the only adverse event noted. The administration of propofol was also versatile being effective, as either a bolus or a bolus followed by an infusion. It appeared to be synergistic with existing therapy. Although further study is needed, these results suggest that propofol may be a very valuable additional agent for the ECT clinician in the management of PIA, which is a common entity in the setting of ECT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17143155     DOI: 10.1097/01.yct.0000235929.46903.67

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  2 in total

1.  Premedication with dexmedetomidine and midazolam attenuates agitation after electroconvulsive therapy.

Authors:  Ayse Mizrak; Senem Koruk; Suleyman Ganidagli; Mahmut Bulut; Unsal Oner
Journal:  J Anesth       Date:  2009-02-22       Impact factor: 2.078

Review 2.  Uncommon but serious complications associated with electroconvulsive therapy: recognition and management for the clinician.

Authors:  Mario A Cristancho; Yesne Alici; John G Augoustides; John P O'Reardon
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.